News
The phase 3 IRAKLIA trial assesses subcutaneous isatuximab via on-body injector vs intravenous (IV) administration, in combination with pomalidomide and dexamethasone, in relapsed/refractory multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback